65,437 trials
Aneurysmal Subarachnoid Hemorrhage
Primary: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation — 32; 35 Participants…
Lung Cancer
Primary: Progression Free Survival (PFS) — 4.8 months
Covid19
Primary: Number of Matched Test Colormetric Interpretation as a Measure of Interrater Reliability — 52; 69; 97; 27 Completed tests
Depression
Primary: Beck Depression Inventory (BDI-II) Score — 21.29 score on a scale
Xerostomia
Primary: Percentage of Participants Who Appropriately Will Self-select the Study Product for Use Under Simulated OTC Conditions [Phase I] — 100; 100 percentage
Vitiligo · Dermatology/Skin - Other
Primary: Molecular Changes From NB-UVB Therapy
Atopic Dermatitis · Atopic Dermatitis Eczema
Primary: Psychological General Well-Being Scale (PGWB) — 68.3; 73.7 score on a scale
Migraine
Primary: Resting State Functional Connectivity — 26.2; 23.3 global efficiency percentage — p=0.04
Leiomyoma · Laparoscopy · Uterine Myomectomy
Primary: Hemoglobin Levels Difference Between Pre and Post Surgery. — 0.76; 0.93 g/dL
Healthy Volunteers
Primary: Go Correct Hits Followed by Button Press — 90.9; 91.6 Percentage of correct responses
Pain
Primary: Pain at 12 Hours — 3.9; 3.7 score on a scale
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
HIV/AIDS
Primary: Mortality at 6 Months — 4; 10; 3; 4 Participants
Pain
Primary: Time Weighted Average Pain Score in Numerical Rating Scores — 4.0; 4.1 score on a scale — p=0.003
Subarachnoid Hemorrhage, Aneurysmal
Primary: The Difference Between the Active and Sham Treatment Groups in Morphine Equivalence Dosage PER DAY — 0.058; 0.24 mg